Kariuki Enoch 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
Zentalis (ZNTL) Director Kariuki Enoch Receives Award of 57,100 RSUs
What Happened Kariuki Enoch, a member of Zentalis Pharmaceuticals' Board of Directors, received an award of 57,100 restricted stock units (RSUs) on June 16, 2026. The grant is reported at $0.00 per unit (no immediate cash outlay or proceeds) and represents a contingent right to receive one share of common stock per RSU upon vesting.
Key Details
- Transaction date: 2026-06-16 (reported on Form 4 filed 2026-06-18) — filing appears timely.
- Transaction type/code: Award/Grant (A).
- Shares/units granted: 57,100 RSUs; reported acquisition value: $0.00.
- Shares owned after transaction: Not stated in the filing.
- Footnote: These RSUs were granted under the Issuer's Non‑Employee Director Compensation Program and vest on the earlier of (a) June 16, 2027, or (b) the next annual meeting of stockholders, subject to continued Board service.
- Additional filing note: Exhibit 24 (Power of Attorney) included.
Context RSUs are a form of equity compensation that convert to shares only upon vesting; they do not generate immediate cash and do not indicate an open‑market purchase or sale. Grants to non‑employee directors are commonly part of routine compensation and reflect compensation structure rather than an immediate trading signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-16+57,100→ 194,465 total
Footnotes (1)
- [F1]Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.